TY - JOUR AU - Huang, Chaodi AU - Huang, Liying AU - Huang, Jianguo AU - Zheng, Xinkai AU - Jiang, Congjun AU - Tom, Kong Ching AU - Wu, U. Tim AU - Huang, WenHsien Ethan AU - Gao, Yunfei AU - Situ, Fangmin AU - Yu, Hai AU - Deng, Liehua AU - Lyu, Jun TI - Competing‐risks model for predicting the prognosis of patients with regressive melanoma based on the SEER database JF - Malignancy Spectrum J2 - Malignancy Spectrum VL - 1 PY - 2024 IS - 2 SP - 123 EP - 135 PG - 13 SN - 2770-9140 DO - 10.1002/msp2.25 UR - https://m2.mtmt.hu/api/publication/34802682 ID - 34802682 LA - English DB - MTMT ER - TY - JOUR AU - Hughes, Sam AU - Srenathan, Hareni AU - Lynch, Magnus AU - Leeman, Hayley TI - Multicentre experience from tertiary skin cancer units on the role of sentinel lymph node biopsy in patients with pT1b melanoma JF - CLINICAL AND EXPERIMENTAL DERMATOLOGY J2 - CLIN EXP DERMATOL VL - 49 PY - 2024 IS - 5 SP - 519 EP - 521 PG - 3 SN - 0307-6938 DO - 10.1093/ced/llad450 UR - https://m2.mtmt.hu/api/publication/34802680 ID - 34802680 LA - English DB - MTMT ER - TY - JOUR AU - Nguyen Canh, Tung AU - Nguyen Huu, Quang AU - Nguyen Hong, Son AU - Nguyen Dinh, Quan AU - Vu Nguyen, Binh AU - Le Thanh, Hien AU - Ta Thi Ha, Phuong AU - Vu Dinh, Tam AU - Nguyen Huu, Sau TI - SENTINEL LYMPH NODE BIOPSY IN THE MANAGEMENT OF PATIENTS WITH MALIGNANT MELANOMA JF - Tạp chí Da liễu học Việt Nam J2 - TC DLH VN VL - 2023 PY - 2024 IS - 42 SP - 37 EP - 44 PG - 8 SN - 1859-4824 DO - 10.56320/tcdlhvn.42.132 UR - https://m2.mtmt.hu/api/publication/34802726 ID - 34802726 AB - Objectives: To evaluate the efficacy of sentinel lymph node biopsy in the treatment of malignant melanoma.Materials and Methods: Thirty-two melanoma patients without distant or clinical lymph node metastasis underwent preoperative lymphoscintigraphy using Tc99m and a handheld gamma probe to identify sentinel lymph nodes for biopsy. In cases with detected sentinel lymph node metastasis, the patient may require total complete lymph node dissection, combined with optional systemic therapy. Follow-up was performed to evaluate the efficacy of this procedure.Results: In 32 melanoma patients, the most common site of primary tumors was the extremity, accounting for 90.6%, with a mean Breslow index (thickness of the primary tumor) of 1.84 mm. The incidence of microscopic lymph node metastasis was 34.4%. For cases with no detected sentinel lymph node metastasis, 100% of patients had a stable condition, and no recurrence or metastasis was detected. In 11 cases with occult nodal metastasis: 2 deaths, 4 patients were treated with chemotherapy, and 5 cases without chemotherapy. The mean duration of hospitalization for the group with sentinel lymph node metastasis was greater than that of the group without sentinel lymph node metastasis, 25.1 ± 3.1 days and 13.5 ± 1.3 days, respectively.Conclusion: Our results suggest that sentinel lymph node biopsy is a less invasive technique for melanoma patients with no clinically detectable lymph node and distant metastases. This procedure has shown initial outcomes, but it is necessary to conduct a study with a larger sample size and a longer follow-up time, as well as comparing it with a control group for accurate evaluation.Received 23 June 2023Revised 22 September 2023Accepted 27 November 2023 LA - English DB - MTMT ER - TY - JOUR AU - Aivazian, Karina TI - Regression in cutaneous melanoma. histological assessment, immune mechanisms and clinical implications TS - histological assessment, immune mechanisms and clinical implications JF - PATHOLOGY J2 - PATHOLOGY VL - 55 PY - 2023 IS - 2 SP - 227 EP - 235 PG - 9 SN - 0031-3025 DO - 10.1016/j.pathol.2022.11.005 UR - https://m2.mtmt.hu/api/publication/33600344 ID - 33600344 N1 - Cited By :1 Export Date: 4 December 2023 CODEN: PTLGA Correspondence Address: Aivazian, K.; St Vincent's Hospital, 390 Victoria Road, Australia; email: karina.aivazian@svha.org.au AB - Tumour regression is an immunologically driven process that results in complete or partial disappearance of tumour cells. This can be observed in histological sections as replacement of tumour cells with fibrosis, angiogenesis, and a variable inflammatory infiltrate. In primary cutaneous melanoma, the prognostic significance of regression has been debated for decades, in part because inconsistent histological criteria are used in prognostication studies. It is broadly accepted that CD8+ T lymphocytes are the primary effectors of the anti-tumour response, but the interplay between melanoma and the immune system is complex, dynamic, and incompletely understood. Sustained progress in unravelling the pathogenesis of melanoma regression has led to the identification of therapeutic targets, culminating in the development of immune checkpoint inhibitors for the management of advanced disease. Modern techniques allow for high-resolution spatial analyses of the tumour microenvironment. Such studies may lead to better understanding of the immune drivers of melanoma regression, thereby facilitating the search for new prognostic and predictive biomarkers to assist clinical decision-making. LA - English DB - MTMT ER - TY - GEN AU - Ana, Eliza Souza Cunha TI - Decision Making in Patients with Initial Positive Deep Margins on Diagnostic Biopsy of Melanoma PY - 2023 UR - https://m2.mtmt.hu/api/publication/34802683 ID - 34802683 LA - English DB - MTMT ER - TY - JOUR AU - Cheng, TW AU - Hartsough, E AU - Giubellino, A TI - Sentinel lymph node assessment in melanoma: current state and future directions JF - HISTOPATHOLOGY J2 - HISTOPATHOLOGY VL - 83 PY - 2023 IS - 5 SP - 669 EP - 684 PG - 16 SN - 0309-0167 DO - 10.1111/his.15011 UR - https://m2.mtmt.hu/api/publication/34162530 ID - 34162530 N1 - Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States Export Date: 19 January 2024 CODEN: HISTD Correspondence Address: Giubellino, A.; Department of Laboratory Medicine and Pathology, United States; email: agiubell@umn.edu LA - English DB - MTMT ER - TY - JOUR AU - Kakish, Hanna AU - Lal, Trisha AU - Thuener, Jason E. AU - Bordeaux, Jeremy S. AU - Mangla, Ankit AU - Rothermel, Luke D. AU - Hoehn, Richard S. TI - Is sentinel lymph node biopsy needed for lentigo maligna melanoma? JF - JOURNAL OF SURGICAL ONCOLOGY J2 - J SURG ONCOL VL - 129 PY - 2023 IS - 4 SP - 804 EP - 812 PG - 9 SN - 0022-4790 DO - 10.1002/jso.27543 UR - https://m2.mtmt.hu/api/publication/34627806 ID - 34627806 LA - English DB - MTMT ER - TY - JOUR AU - Mir, Espinosa Y. AU - Caballero, Aguirrechu I. AU - García, Gómez R. AU - Quesada, Peña S. AU - López, Caballero N. AU - Soriano, García J.L. AU - de, la Caridad Osorio M. AU - Gracia, Medina E.A. AU - Ortega, Carballosa A. AU - Arteaga, Hernández E. TI - Vemurafenib-cobimetinib en pacientes con melanoma maligno metastásico BRAF-mutado en progresión [Vemurafenib-cobimetinib in patients with progressive BRAF-mutated metastatic malignant melanoma] JF - REVISTA CUBANA DE INVESTIGACIONES BIOMÉDICAS J2 - REV CUB INVEST BIOMED VL - 42 PY - 2023 IS - 1 SN - 0864-0300 UR - https://m2.mtmt.hu/api/publication/33999789 ID - 33999789 N1 - Instituto Nacional de Oncología y Radiobiología (INOR), La Habana, Cuba Hospital Clínico Quirúrgico "Hermanos Ameijeiras" (HHA), La Habana, Cuba Instituto de Ciencias Médicas Victoria de Girón, La Habana, Cuba Export Date: 6 June 2023 CODEN: RCIBE Correspondence Address: Caballero Aguirrechu, I.; Hospital Clínico Quirúrgico "Hermanos Ameijeiras" (HHA), La Habana, Cuba; email: iraidacaballero@yahoo.es LA - Spanish DB - MTMT ER - TY - JOUR AU - Țăpoi, Dana Antonia AU - Derewicz, Diana AU - Gheorghișan-Gălățeanu, Ancuța-Augustina AU - Dumitru, Adrian Vasile AU - Ciongariu, Ana Maria AU - Costache, Mariana TI - The Impact of Clinical and Histopathological Factors on Disease Progression and Survival in Thick Cutaneous Melanomas JF - BIOMEDICINES J2 - BIOMEDICINES VL - 11 PY - 2023 IS - 10 PG - 16 SN - 2227-9059 DO - 10.3390/biomedicines11102616 UR - https://m2.mtmt.hu/api/publication/34224287 ID - 34224287 AB - Thick cutaneous melanomas (Breslow depth > 4 mm) are locally advanced tumors, generally associated with poor prognosis. Nevertheless, these tumors sometimes display unpredictable behavior. This study aims to analyze clinical and histopathological features that can influence the prognosis of thick melanomas. This is a retrospective study on 94 thick primary cutaneous melanomas diagnosed between 2012 and 2018 that were followed-up for at least five years to assess disease progression and survival. We evaluated the age, gender, tumor location, histological subtype, Breslow depth, Clark level, resection margins, mitotic index, the presence/absence of ulceration, necrosis, regression, microsatellites, neurotropism, lymphovascular invasion, and the pattern of tumor-infiltrating lymphocytes, and their association with disease progression and survival. By conducting univariate analysis, we found that progression-free survival (PFS) was significantly associated with female gender, the superficial spreading melanoma (SSM) subtype, mitotic index, necrosis, microsatellites, and perineural invasion. Overall survival (OS) was significantly associated with female gender, Breslow depth, SSM subtype, necrosis, microsatellites, and perineural invasion. Through multivariate Cox proportional hazards regression, we found that the only factors associated with PFS were Breslow depth, necrosis, microsatellites, and perineural invasion, while the factors associated with OS were Breslow depth, necrosis, microsatellites, and perineural invasion. Certain histopathological features such as Breslow depth, necrosis, microsatellites, and perineural invasion could explain differences in disease evolution. This is one of the first studies to demonstrate an association between necrosis and perineural invasion and outcomes in patients with thick melanomas. By identifying high-risk patients, personalized therapy can be provided for improved prognosis. LA - English DB - MTMT ER - TY - JOUR AU - Huang, Hanzi AU - Fu, Ziyao AU - Ji, Jiang AU - Huang, Jiuzuo AU - Long, Xiao TI - Predictive Values of Pathological and Clinical Risk Factors for Positivity of Sentinel Lymph Node Biopsy in Thin Melanoma: A Systematic Review and Meta-Analysis JF - FRONTIERS IN ONCOLOGY J2 - FRONT ONCOL VL - 12 PY - 2022 PG - 10 SN - 2234-943X DO - 10.3389/fonc.2022.817510 UR - https://m2.mtmt.hu/api/publication/32784741 ID - 32784741 N1 - Export Date: 17 April 2022 Correspondence Address: Huang, J.; Department of Plastic Surgery, China; email: hjz1983@126.com Correspondence Address: Long, X.; Department of Plastic Surgery, China; email: pumclongxiao@126.com LA - English DB - MTMT ER - TY - JOUR AU - Kim, Daniel AU - Chu, Stanley AU - Khan, Ayesha U. AU - Compres, Elsy V AU - Zhang, Hui AU - Gerami, Pedram AU - Wayne, Jeffrey D. TI - Risk factors and patterns of recurrence after sentinel lymph node biopsy for thin melanoma JF - ARCHIVES OF DERMATOLOGICAL RESEARCH J2 - ARCH DERMATOL RES VL - 314 PY - 2022 IS - 3 SP - 285 EP - 292 PG - 8 SN - 0340-3696 DO - 10.1007/s00403-021-02229-8 UR - https://m2.mtmt.hu/api/publication/32382630 ID - 32382630 N1 - Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States Division of Surgical Oncology, Department of Surgery, Feinberg School of Medicine, Northwestern University, 676 North St. Clair Street, Arkes 650, Chicago, IL 60611, United States Division of Biostatistics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States Robert H. Lurie Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States Export Date: 20 November 2021 CODEN: ADMFA Correspondence Address: Wayne, J.D.; Department of Dermatology, United States; email: jwayne@northwestern.edu Funding details: Melanoma Research Foundation, MRF, SP0043559 Funding text 1: This study was partially supported by the IDP Foundation and the Melanoma Research Foundation (SP0043559). AB - While having a thin melanoma (defined as AJCC 8 T1 stage tumor <= 1.0 mm) with negative sentinel lymph node biopsy (SLNB) provides an excellent prognosis, some patients still develop recurrence and die. To determine risk factors for any recurrence (local/in-transit, nodal, distant) in thin melanoma patients with negative SLNB and assess survival outcomes. Retrospective review of thin melanomas with negative SLNB from 1999 to 2018 was performed. Two hundred and nine patients were identified. Clinicopathologic characteristics of the primary melanoma were collected. Patterns of recurrence for local/in-transit, nodal or distant recurrence and survival outcomes were analyzed. Eighteen patients (8.6%) developed recurrence: 3 (1.9%) local/in-transit, 4 (2.9%) regional/nodal, and 11 (5.3%) distant recurrence during a median follow-up time of 62 months. A multivariate Cox regression model showed that head and neck site (HR 3.52), ulceration (HR 10.8), and mitotic rate (HR 1.39) were significant risk factors for recurrence. Median time to first recurrence was 49 months. Patients with recurrence had a significantly worse 5 year overall survival than those without recurrence (82.2 vs 99.2%). A retrospective single center study and limited sample size. Did not factor in possible false negative SLNBs when calculating hazard ratios. For thin melanoma patients with negative SLNB, heightened surveillance is warranted for those with ulceration, primary tumor location on the head or neck, and elevated mitotic rate. LA - English DB - MTMT ER - TY - JOUR AU - Ricci, Costantino AU - Dika, Emi AU - Lambertini, Martina AU - Ambrosi, Francesca AU - Chiarucci, Federico AU - Chillotti, Stefano AU - Fiorentino, Michelangelo AU - Fabbri, Erich AU - Tassone, Daniela AU - Veronesi, Giulia AU - Tartari, Federico AU - Corti, Barbara TI - The EORTC protocol for sentinel lymph node biopsy (SLNB) reveals a high number of nodal nevi and a strong association with nevus-associated melanoma JF - PATHOLOGY RESEARCH AND PRACTICE J2 - PATHOL RES PRACT VL - 233 PY - 2022 PG - 6 SN - 0344-0338 DO - 10.1016/j.prp.2022.153805 UR - https://m2.mtmt.hu/api/publication/33447481 ID - 33447481 AB - Background: The diagnosis of nodal nevi (NN) is challenging as they mimic melanoma metastases (MM), with a detection rate mostly ranging between 1% and 11% in sentinel lymph node biopsy (SLNB). Herein, we assessed the incidence of NN and the association with the clinical-pathological features of primary melanoma, adopting the updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for SLNB. Methods: All cases of paired melanoma and SLNB were retrospectively evaluated (April 2019-May 2020). Appropriate statistical tests were adopted, with significant variables included in the logistic regression model. Results: 81 patients and a total of 186 lymph nodes (LNs) were included. Eleven patients had only NN and 4 had both NN and MM (18.5%); 29 LNs (15.6%) showed at least one NN and 12 (6.5%) showed more than one NN (a total amount of 43 NN was detected). All NN and none MM stained for p16. NN were associated with age < 60 years (p: 0.042), no ulceration (p: 0.025) and nevus-associated melanoma (NAM) (p: 0.018), with this latter being the only predictor at the logistic regression model (p: 0.022). Conclusions: The updated EORTC protocol shows a high number of NN and highlights a strong association with NAM. LA - English DB - MTMT ER - TY - THES AU - Sabine, Röber TI - Analyse prognostischer Faktoren zur Risikoabschätzung einer Lymphknotenmetastasierung nach Sentinellymphonodektomie bei malignen Melanomen mit einer Tumordicke ≤ 1,00 mm und malignen Melanomen mit einer Tumordicke ≥ 3,5 mm. Eine retrospektive Studie TS - Eine retrospektive Studie PY - 2022 UR - https://m2.mtmt.hu/api/publication/34802690 ID - 34802690 LA - German DB - MTMT ER - TY - JOUR AU - Upadhyaya, Siddhi N. AU - Knackstedt, Rebecca W. AU - Ko, Jennifer S. AU - Gastman, Brian R. TI - The Use and Technique of Sentinel Node Biopsy for Skin Cancer JF - PLASTIC AND RECONSTRUCTIVE SURGERY J2 - PLAST RECONSTR SURG VL - 149 PY - 2022 IS - 5 SP - 995e EP - 1008e PG - 14 SN - 0032-1052 DO - 10.1097/PRS.0000000000009010 UR - https://m2.mtmt.hu/api/publication/32820597 ID - 32820597 N1 - Export Date: 4 December 2023 CODEN: PRSUA Correspondence Address: Gastman, B.R.; Cleveland Clinic, 9500 Euclid Avenue, A60, United States; email: gastmab@ccf.org AB - Learning Objectives: After studying this article, the participant should be able to: 1. Understand the indications for and prognostic value of sentinel lymph node biopsy in skin cancer. 2. Learn the advantages and disadvantages of various modalities used alone or in combination when performing sentinel lymph node biopsy. 3. Understand how to perform sentinel lymph node biopsy in skin cancer patients. Summary: Advances in technique used to perform sentinel lymph node biopsy to assess lymph node status have led to increased accuracy of the procedure and improved patient outcomes. LA - English DB - MTMT ER - TY - JOUR AU - Weitemeyer, M.B. AU - Helvind, N.M. AU - Brinck, A.M. AU - Hölmich, L.R. AU - Chakera, A.H. TI - More sentinel lymph node biopsies for thin melanomas after transition to AJCC 8th edition do not increase positivity rate: A Danish population-based study of 7148 patients JF - JOURNAL OF SURGICAL ONCOLOGY J2 - J SURG ONCOL VL - 125 PY - 2022 IS - 3 SP - 498 EP - 508 PG - 11 SN - 0022-4790 DO - 10.1002/jso.26723 UR - https://m2.mtmt.hu/api/publication/32501827 ID - 32501827 N1 - Department of Plastic and Reconstructive Surgery, Herlev and Gentofte University Hospital, Herlev, Denmark Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark Export Date: 20 November 2021 CODEN: JSONA Correspondence Address: Weitemeyer, M.B.; Department of Plastic and Reconstructive Surgery, Denmark; email: marie.brinch@hotmail.com AB - Background: We evaluated the outcome of sentinel lymph node biopsies (SLNB) in patients with thin melanoma before and after the implementation of AJCC 8th edition (AJCC8) and identified predictors of positive sentinel lymph nodes (+SLN). Methods: Patients diagnosed with T1 melanomas (Breslow thickness ≤1 mm) during 2016–2017 as per AJCC 7th edition (AJCC7) (n = 3414) and 2018–2019 as per AJCC8 (n = 3734) were identified in the Danish Melanoma Database. Results: More SLNBs were performed in the AJCC8 cohort compared to the AJCC7 (22.2% vs. 16.2%, p < 0.001), with no significant difference in +SLN rates (4.7% vs. 6.7%, p = 0.118). In the AJCC7 + SLN subgroup, no melanomas were ulcerated, 94.6% had mitotic rate (MR) ≥ 1, 67.6% were ≥0.8 mm and 32.4% would be T1a according to AJCC8. In the AJCC8 + SLN subgroup, 10.3% were ulcerated, 74.4% had MR≥ 1, 97.4% were ≥0.8 mm and 23.1% would be T1a according to AJCC7. On multivariable analysis younger age and MR ≥ 1 were significant predictors of +SLN. Conclusion: More SLNBs were performed in T1 melanomas after transition to AJCC8 without an increase in +SLN rate. None of the AJCC8 T1b criteria were significant predictors of +SLN. We suggest that mitosis and younger age should be considered as indications for SLNB in thin melanoma. © 2021 Wiley Periodicals LLC. LA - English DB - MTMT ER - TY - JOUR AU - Aivazian, Karina AU - Ahmed, Tasnia AU - El Sharouni, Mary-Ann AU - Stretch, Jonathan R. AU - Saw, Robyn P. M. AU - Spillane, Andrew J. AU - Shannon, Kerwin F. AU - Ch'ng, Sydney AU - Nieweg, Omgo E. AU - Thompson, John F. AU - Lo, Serigne N. AU - Scolyer, Richard A. TI - Histological regression in melanoma: impact on sentinel lymph node status and survival JF - MODERN PATHOLOGY J2 - MODERN PATHOL VL - 34 PY - 2021 IS - 11 SP - 1999 EP - 2008 PG - 10 SN - 0893-3952 DO - 10.1038/s41379-021-00870-2 UR - https://m2.mtmt.hu/api/publication/32336853 ID - 32336853 N1 - Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia Tissue Pathology & Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia Department of Dermatology, University Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia Export Date: 20 November 2021 CODEN: MODPE Correspondence Address: Scolyer, R.A.; Melanoma Institute Australia, Australia; email: richard.scolyer@health.nsw.gov.au Funding details: National Health and Medical Research Council, NHMRC, APP1141295 Funding details: Melanoma Institute Australia, MIA Funding text 1: KA is supported by Deborah McMurtrie and John McMurtrie AM through the McMurtrie Cancer Pathology Fellowship. MAES was supported by a Research Fellowship Grant from the European Association of Dermatology and Venereology (EADV). JFT and RAS are recipients of an Australian National Health and Medical Research Council (NHMRC) Program Grant (APP1093017). RAS is supported by an NHMRC Practitioner Fellowship (APP1141295). RPMS is supported by Melanoma Institute Australia. Support from the Cameron Family as well as from colleagues at Melanoma Institute Australia, Royal Prince Alfred Hospital and NSW Health Pathology is gratefully acknowledged. AB - Regression in melanoma is an immunological phenomenon that results in partial or complete replacement of the tumor with variably vascular fibrous tissue, often accompanied by pigment-laden macrophages and chronic inflammation. In some cases, tumor-infiltrating lymphocytes (TILs) may represent the earliest phase of this process. The prognostic significance of regression has long been a matter of debate, with inconsistent findings reported in the literature to date. This study sought to determine whether regression in primary cutaneous melanomas predicted sentinel lymph node (SLN) status and survival outcomes in a large cohort of patients managed at a single centre. Clinical and pathological parameters for 8,693 consecutive cases were retrieved. Associations between regression and SLN status, overall survival (OS), melanoma-specific survival (MSS) and recurrence-free survival (RFS) were investigated using logistic and Cox regression. Histological evidence of regression was present in 1958 cases (22.5%). Regression was significantly associated with lower Breslow thickness, lower mitotic rate, and absence of ulceration (p < 0.0001). Multivariable analysis showed that regression in combination with TILs independently predicted a negative SLN biopsy (OR 0.33; 95% C.I. 0.20-0.52; p < 0.0001). Patients whose tumors showed both regression and TILs had the highest 10-year OS (65%, 95% C.I. 59-71%), MSS (85%, 95% C.I. 81-89%), and RFS (60%, 95% C.I. 54-66%). On multivariable analyses, the concurrent presence of regression and TILs independently predicted the lowest risk of death from melanoma (HR 0.69; 95% C.I. 0.51-0.94; p = 0.0003) as well as the lowest rate of disease recurrence (HR 0.71; 95% C.I. 0.58-0.85; p < 0.0001). However, in contrast, in the subgroup analysis of Stage III patients, the presence of regression predicted the lowest OS and RFS, with MSS showing a similar trend. Overall, these findings indicate a prognostically favorable role of regression in primary cutaneous melanoma. However, in Stage III melanoma patients, regression may be a marker of more aggressive disease. LA - English DB - MTMT ER - TY - JOUR AU - Gil, J. AU - Rezeli, M. AU - Lutz, E.G. AU - Kim, Y. AU - Sugihara, Y. AU - Malm, J. AU - Semenov, Y.R. AU - Yu, K.-H. AU - Nguyen, N. AU - Wan, G. AU - Kemény, Lajos Vince AU - Kárpáti, Sarolta AU - Németh, István Balázs AU - Marko‐varga, G. TI - An observational study on the molecular profiling of primary melanomas reveals a progression dependence on mitochondrial activation JF - CANCERS J2 - CANCERS VL - 13 PY - 2021 IS - 23 PG - 19 SN - 2072-6694 DO - 10.3390/cancers13236066 UR - https://m2.mtmt.hu/api/publication/32527768 ID - 32527768 N1 - Division of Oncology, Department of Clinical Sciences, Lund University, Lund, 222 42, Sweden Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, Malmö, 205 02, Sweden Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, Lund, 222 42, Sweden Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, 1085, Hungary Data Convergence Drug Research Center, Therapeutics and Biotechnology Division, Korea Research Institute of Chemical Technology (KRICT), Daejeon, 34114, South Korea Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02110, United States Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, United States Department of Dermatology and Allergology, University of Szeged, Szeged, 6720, Hungary Chemical Genomics Global Research Lab, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, 03722, South Korea 1st Department of Surgery, Tokyo Medical University, Tokyo, 160‐8582, Japan Export Date: 8 December 2021 Correspondence Address: Gil, J.; Division of Oncology, Sweden; email: jeovanis.gil_valdes@med.lu.se LA - English DB - MTMT ER - TY - JOUR AU - Morrison, Steven AU - Han, Dale TI - Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma JF - CURRENT TREATMENT OPTIONS IN ONCOLOGY J2 - CURR TREAT OPTION ON VL - 22 PY - 2021 IS - 3 PG - 19 SN - 1527-2729 DO - 10.1007/s11864-021-00819-2 UR - https://m2.mtmt.hu/api/publication/31920993 ID - 31920993 N1 - Cited By :2 Export Date: 20 November 2021 CODEN: CTOOB Correspondence Address: Han, D.; Division of Surgical Oncology, 3181 SW Sam Jackson Park Road, United States; email: handal@ohsu.edu Chemicals/CAS: dabrafenib, 1195765-45-7, 1195768-06-9; ipilimumab, 477202-00-9; nivolumab, 946414-94-4; pembrolizumab, 1374853-91-4; trametinib, 1187431-43-1, 871700-17-3 AB - Opinion statement The vast majority of patients newly diagnosed with melanoma present with clinically localized disease, and sentinel lymph node biopsy (SLNB) is a standard of care in the management of these patients, particularly in intermediate thickness cases, in order to provide important prognostic data. However, SLNB also has an important role in the management of patients with other subtypes of melanoma such as thick melanomas, certain thin melanomas, and specific histologic variants of melanoma such as desmoplastic melanoma. Furthermore, there have been technical advances in the SLNB technique, such as the development of newer radiotracers and use of SPECT/CT, and there is some data to suggest performing a SLNB may be therapeutic. Finally, the management of patients with a positive sentinel lymph node (SLN) has undergone dramatic changes over the past several years based on the results of recent important clinical trials. Treatment options for patients with SLN metastases now include surveillance, completion lymph node dissection, and adjuvant therapy with checkpoint inhibitors and targeted therapy. SLNB continues to play a crucial role in the management of patients with melanoma, allowing for risk stratification, potential regional disease control, and further treatment options for patients with a positive SLN. LA - English DB - MTMT ER - TY - JOUR AU - Nikolaeva, E. A. AU - Krylov, A. S. AU - Ryzhkov, A. D. AU - Abdulova, L. Y. AU - Bilik, M. E. AU - Zakharova, T. V. AU - Baryshnikov, K. A. TI - Прогностические факторы метастазирования в сторожевые лимфатические узлы у больных меланомой различной толщины по классификатору Бреслоу [Predictive Factors for Metastasis of Skin Melanoma of Varying Thickness According to Breslow to Sentinel Lymph Nodes] JF - Онкологический журнал: лучевая диагностика, лучевая терапия VL - 4 PY - 2021 IS - 3 SP - 18 EP - 25 PG - 8 SN - 2587-7593 DO - 10.37174/2587-7593-2021-4-3-18-25 UR - https://m2.mtmt.hu/api/publication/34802694 ID - 34802694 AB - Purpose : To evaluate the prognostic factors in patients with Breslow skin melanoma of various thicknesses that affect the incidence of metastases in the signal lymph nodes (SLN). LA - Russian DB - MTMT ER - TY - JOUR AU - Subramanian, S. AU - Han, G. AU - Olson, N. AU - Leong, S.P. AU - Kashani-Sabet, M. AU - White, R.L. AU - Zager, J.S. AU - Sondak, V.K. AU - Messina, J.L. AU - Pockaj, B. AU - Kosiorek, H.E. AU - Vetto, J. AU - Fowler, G. AU - Schneebaum, S. AU - Han, D. TI - Regression is significantly associated with outcomes for patients with melanoma JF - SURGERY J2 - SURGERY (UNITED STATES) VL - 170 PY - 2021 IS - 5 SP - 1487 EP - 1494 PG - 8 SN - 0039-6060 DO - 10.1016/j.surg.2021.05.010 UR - https://m2.mtmt.hu/api/publication/32501825 ID - 32501825 N1 - Division of Surgical Oncology, Oregon Health & Science University, Portland, OR, United States Department of Epidemiology and Biostatistics, School of Public Health, Texas A & M University, College Station, TX, United States California Pacific Medical Center and Research Institute, San Francisco, CA, United States Levine Cancer Institute, Carolinas Medical Center, Atrium Health, Charlotte, NC, United States Moffitt Cancer Center, Tampa, FL, United States Mayo Clinic, Phoenix, AZ Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel Cited By :1 Export Date: 20 November 2021 CODEN: SURGA Correspondence Address: Han, D.; Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Mail Code: L619, United States; email: handal@ohsu.edu AB - Background: The prognostic significance of regression in melanoma is debated. We present a large multicenter study correlating regression with sentinel lymph node metastasis and melanoma-specific survival. Methods: The Sentinel Lymph Node Working Group database was reviewed from 1993 to 2018. Patients with known regression and sentinel lymph node status were included. Clinicopathologic factors were correlated with regression, sentinel lymph node status, and melanoma-specific survival. Results: There were 4,790 patients; median follow-up was 39.6 months. Regression was present in 1,081 (22.6%) cases, and 798 (16.7%) patients had sentinel lymph node metastases. On multivariable analysis, male sex, truncal tumors, and decreasing thickness were significantly associated with regression (P < .05), whereas head/neck or leg tumors had lower rates of regression (P < .05). Regression was significantly correlated with a decreased risk of sentinel lymph node disease on multivariable analysis (odds ratio 0.68, 95% confidence interval 0.54–0.85; P = .0008). Multivariable analysis also showed that increasing age, male sex, increasing thickness, ulceration, lymphovascular invasion, microsatellitosis, and sentinel lymph node metastasis were significantly (P < .05) associated with worse melanoma-specific survival, while regression was significantly associated with better melanoma-specific survival (hazard ratio 0.75, 95% confidence interval 0.57–0.99; P = .043). Conclusion: This large study shows that regression is significantly associated with better outcomes in patients with melanoma and is correlated with a lower risk of sentinel lymph node metastasis and a better melanoma-specific survival. © 2021 Elsevier Inc. LA - English DB - MTMT ER - TY - JOUR AU - Whitman, E.D. AU - Koshenkov, V.P. AU - Gastman, B.R. AU - Lewis, D. AU - Hsueh, E.C. AU - Pak, H. AU - Trezona, T.P. AU - Davidson, R.S. AU - McPhee, M. AU - Michael, Guenther J. AU - Toomey, P. AU - Smith, F.O. AU - Beitsch, P.D. AU - Lewis, J.M. AU - Ward, A. AU - Young, S.E. AU - Shah, P.K. AU - Quick, A.P. AU - Martin, B.J. AU - Zolochevska, O. AU - Covington, K.R. AU - Monzon, F.A. AU - Goldberg, M.S. AU - Cook, R.W. AU - Fleming, M.D. AU - Hyams, D.M. AU - Vetto, J.T. TI - Integrating 31-gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction JF - JCO PRECISION ONCOLOGY J2 - JCO PRECIS ONCOL VL - 5 PY - 2021 SP - 1466 EP - 1479 PG - 14 SN - 2473-4284 DO - 10.1200/PO.21.00162 UR - https://m2.mtmt.hu/api/publication/32501826 ID - 32501826 N1 - Carol G. Simon Cancer at Morristown Medical Center, Atlantic Health System, Morristown, NJ, United States Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States Cleveland Clinic Lerner Research Institute, Cleveland, OH, United States Medical City Dallas Hospital, Dallas, TX, United States Department of Surgery, St Louis University, St Louis, MO, United States General Surgery Abington Memorial Hospital, Abington, PA, United States Oregon Melanoma Center, Springfield, OR, United States Morton Plant Mease Healthcare, Safety Harbor, FL, United States Advent Health Cancer Institute, Orlando, FL, United States St Elizabeth Physicians General & Vascular Surgery, Ft Mitchell, KY, United States Florida State University College of Medicine, Bradenton, FL, United States RWJ Barnabas Health, Livingston, NJ, United States North Texas Melanoma Center, Dallas, TX, United States University of Tennessee Graduate School of Medicine, Knoxville, TN, United States SCL Health, Denver, CO, United States Castle Biosciences Inc, Friendswood, TX, United States Division of Surgical Oncology, The University of Tennessee Health Science Center, Memphis, TN, United States Desert Surgical Oncology, Rancho MirageCA, United States Oregon Health & Science University, Portland, OR, United States Export Date: 20 November 2021 Correspondence Address: Cook, R.W.505 S. Friendswood Drive, Ste 401, United States; email: rcook@castlebiosciences.com Funding text 1: Supported by Castle Biosciences Inc. AB - PURPOSE National guidelines recommend sentinel lymph node biopsy (SLNB) be offered to patients with . 10% likelihood of sentinel lymph node (SLN) positivity. On the other hand, guidelines do not recommend SLNB for patients with T1a tumors without high-risk features who have, 5% likelihood of a positive SLN. However, the decision to perform SLNB is less certain for patients with higher-risk T1 melanomas in which a positive node is expected 5%-10% of the time. We hypothesized that integrating clinicopathologic features with the 31-gene expression profile (31-GEP) score using advanced artificial intelligence techniques would provide more precise SLN risk prediction. METHODS An integrated 31-GEP (i31-GEP) neural network algorithm incorporating clinicopathologic features with the continuous 31-GEP score was developed using a previously reported patient cohort (n = 1,398) and validated using an independent cohort (n = 1,674). RESULTS Compared with other covariates in the i31-GEP, the continuous 31-GEP score had the largest likelihood ratio (G2 = 91.3, P, .001) for predicting SLN positivity. The i31-GEP demonstrated high concordance between predicted and observed SLN positivity rates (linear regression slope = 0.999). The i31-GEP increased the percentage of patients with T1-T4 tumors predicted to have, 5% SLN-positive likelihood from 8.5% to 27.7% with a negative predictive value of 98%. Importantly, for patients with T1 tumors originally classified with a likelihood of SLN positivity of 5%-10%, the i31-GEP reclassified 63% of cases as having, 5% or . 10% likelihood of positive SLN, for a more precise, personalized, and clinically actionable SLN-positive likelihood estimate. CONCLUSION These data suggest the i31-GEP could reduce the number of SLNBs performed by identifying patients with likelihood under the 5% threshold for performance of SLNB and improve the yield of positive SLNBs by identifying patients more likely to have a positive SLNB. © 2021 by American Society of Clinical Oncology LA - English DB - MTMT ER -